Table 4 A summary of clinical trials based on the administration of CAR T cells to target EGFR, in particular HER2, -positive tumor cells registered in ClinicalTrails.gov (September 2021)
Condition | CAR- immune cell | Study phase | Status | Participant number | Location | NCT number |
|---|---|---|---|---|---|---|
Glioma | EGFR-vIII CAR-T | 1 | Terminated | 11 | USA | NCT02209376 |
Glioma | EGFR-vIII CAR-T | 1 | Terminated | 2 | USA | NCT03283631 |
Glioma | EGFR-vIII CAR-T | 1 | Terminated | 3 | USA | NCT02664363 |
Central nervous system tumor | HER2 CAR-T | 1 | Recruiting | 48 | USA | NCT03500991 |
Brain tumor Breast cancer | HER2 CAR-T | 1 | Recruiting | 39 | USA | NCT03696030 |
Glioma | EGFR-vIII CAR-T | 1/2 | Completed | 18 | USA | NCT01454596 |
Various cancers | HER2 CAR-T | 1/2 | Withdrawn | 0 | China | NCT02713984 |
Lung cancer | HER2 CAR-T | 1 | Recruiting | 30 | China | NCT03198052 |
Breast cancer Gastric cancer | HER2 CAR-T | 1 | Recruiting | 220 | USA | NCT04650451 |
Glioma | EGFR-vIII CAR-T | 1 | Unknown | 20 | China | NCT02844062 |
Central nervous system tumor | HER2 CAR-T | 1 | Recruiting | 28 | USA | NCT02442297 |
Ependymoma | HER2 CAR-T | 1 | Not yet recruiting | 50 | USA | NCT04903080 |
Various cancers | HER2 CAR-T | 1 | Recruiting | 45 | USA | NCT03740256 |
Glioma | EGFR-vIII CAR-T | 1 | Completed | 7 | USA | NCT03726515 |
Various cancers | HER2 CAR-T | 1 | Recruiting | 18 | USA | NCT04660929 |
Glioma | HER2 CAR-T | 1 | Completed | 16 | USA | NCT01109095 |
Peritoneal carcinoma metastatic | HER2 CAR-T | Early 1 | Not yet recruiting | 18 | China | NCT04684459 |
Various cancers | HER2 CAR-T | 1 | Recruiting | 15 | China | NCT04511871 |
Sarcoma | HER2 CAR-T | 1 | Active, not recruiting | 36 | USA | NCT00902044 |
Esophagus cancer Hepatoma Glioma Gastric cancer | EGFR-vIII CAR-T | 1/2 | Recruiting | 50 | China | NCT03941626 |
Breast cancer | HER2 CAR-T | 1/2 | Withdrawn | 0 | China | NCT02547961 |
Pancreatic cancer | HER2 CAR-T | Early1 | Unknown | 10 | China | NCT03267173 |